Corrigendum to “LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumour targeting and NIR, MRI and CT imaging” [Biomaterials 71C (2015) 84–99] (S0142961215006432) (10.1016/j.biomaterials.2015.07.055);LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging

Biomaterials

Volumn 71, Issue , 2015, Pages 84-99

  Roy, Kislay ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Bovine lactoferrin; Colon cancer stem cells; Fe3O4; Locked nucleic acid (LNA); Nanotheranostic; Survivin

Indexed keywords

CALCIUM; CELL ADHESION; CELL DEATH; CELLS; CHEMICAL ACTIVATION; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; DISEASES; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMES; GENE EXPRESSION; INFRARED DEVICES; LOCKS (FASTENERS); MAGNETIC RESONANCE IMAGING; MAMMALS; MITOCHONDRIA; MOLECULES; NUCLEIC ACIDS; PROTEINS; STEM CELLS; TAR; TUMORS;

BOVINE LACTOFERRIN; COLON CANCER; LOCKED NUCLEIC ACID; NANOTHERANOSTIC; SURVIVIN;

CELL SIGNALING;

ALGINIC ACID; APTAMER; CALCIUM PHOSPHATE; CD133 ANTIGEN; CHITOSAN; CYTOCHROME C; CYTOKINE; EPITHELIAL CELL ADHESION MOLECULE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HEMOGLOBIN; HERMES ANTIGEN; INTERLEUKIN 27; IRON OXIDE; KERATINOCYTE DERIVED CHEMOKINE; LACTOFERRIN; LOCKED NUCLEIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NANOCARRIER; NUCLEOLIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; SURVIVIN 2B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ZINC; CADHERIN; CELL ADHESION MOLECULE; FERRIC ION; FERRIC OXIDE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NANOMATERIAL; OLIGONUCLEOTIDE; PEPTIDE; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; COLON TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; DEPOLARIZATION; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVATION; ERYTHROCYTE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOMODULATION; MACROPHAGE; MALE; MITOCHONDRION; MONOCYTE; MOUSE; MULTIMODAL IMAGING; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TUMOR REGRESSION; WNT SIGNALING PATHWAY; ANIMAL; BOVINE; CHEMISTRY; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; METABOLISM; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; APTAMERS, NUCLEOTIDE; CADHERINS; CATTLE; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; FERRIC COMPOUNDS; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HETEROGRAFTS; LACTOFERRIN; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NANOSTRUCTURES; OLIGONUCLEOTIDES; PEPTIDES; SPECTROSCOPY, NEAR-INFRARED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941578541     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.05.041     Document Type: Erratum

References (68)

1. Pichler B.J., Kolb A., Nägele T., Schlemmer H.-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J. Nucl. Med. 2010, 51:333-336.
2. Martí-Bonmatí L., Sopena R., Bartumeus P., Sopena P. Multimodality imaging techniques. Contrast Media Mol. Imaging 2010, 5:180-189.
3. Misri R. Multimodality Imaging 2013.
4. Oztas Y.E., Ozgunes N. Lactoferrin: multifunctional protein. Adv. Mol. Med. 2005, 1:149-154.
5. Tsuda H., Kozu T., Iinuma G., Ohashi Y., Saito Y., Saito D., et al. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 2010, 23:399-409.
6. Kanwar R.K., Kanwar J.R. Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein Pept. Lett. 2013, 20:450-458.
7. Troost F.J., Steijns J., Saris W.H., Brummer R.-J.M. Gastric digestion of bovine lactoferrin in vivo in adults. J. Nutr. 2001, 131:2101-2104.
8. King J.C., Cummings G.E., Guo N., Trivedi L., Readmond B.X., Keane V., et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J. Pediatr. Gastroenterol. Nutr. 2007, 44:245-251.
9. Kanwar J.R., Mahidhara G., Kanwar R.K. Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine (Lond.) 2012, 7:1521-1550.
10. Kanwar J.R., Mahidhara G., Roy K., Sasidharan S., Krishnakumar S., Prasad N., et al. Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine (Lond.) 2014, 1-21.
11. Mahidhara G., Kanwar R., Roy K., Kanwar J.R. Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. Int. J. Nanomed. 2015, 10:1-18.
12. Gupta I., Sehgal R., Kanwar R.K., Punj V., Kanwar J.R. Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine (Lond.) 2015, 10(8):1289-1314. 10.2217/NNM.14.209.
13. Samarasinghe R.M., Kanwar R.K., Kanwar J.R. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials 2014, 35(26):7522-7534.
14. Samarasinghe R.M., Kanwar R.K., Kumar K., Kanwar J.R. Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers. Nanomedicine (Lond.) 2014, 1-19.
15. Kanwar J.R., Roy K., Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 2011, 46:459-477.
16. Subramanian N., Raghunathan V., Kanwar J.R., Kanwar R.K., Elchuri S.V., Khetan V., et al. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol. Vis. 2012, 18:2783.
17. Kanwar J.R., Kanwar R.K., Mahidhara G., Cheung C.H.A. Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells. Aust. J. Chem. 2012, 65:5-14.
18. Roy K., Kanwar R.K., Cheung C.H.A., Fleming C.L., Veedu R.N., Krishnakumar S., et al. Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Adv. 2015, 5:29008-29016.
19. Kanwar J.R., Palmano K.P., Sun X.Y., Kanwar R.K., Gupta R., Haggarty N., et al. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol. Cell Biol. 2008, 86:277-288.
20. Barrère F., van Blitterswijk C.A., de Groot K. Bone regeneration: molecular and cellular interactions with calcium phosphate ceramics. Int. J. Nanomed. 2006, 1:317.
21. Gades M.D., Stern J.S. Chitosan supplementation and fat absorption in men and women. J. Acad. Nutr. Diet. 2005, 105:72-77.
22. Tugcu-Demiroz F., Acarturk F., Takka S., Konus-Boyunaga O. Evaluation of alginate based mesalazine tablets for intestinal drug delivery. Eur. J. Pharm. Biopharm. - Off. J. Arbeitsgemeinschaft Pharm. Verfahr. e.V. 2007, 67:491-497.
23. Roy K., Kanwar R.K., Krishnakumar S., Cheung C.H.A., Kanwar J.R. Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. Int. J. Nanomed. 2015, 10:1019.
24. Giavalisco M., Ferguson H., Koekemoer A., Dickinson M., Alexander D., Bauer F., et al. The great observatories origins deep survey: initial results from optical and near-infrared imaging. Astrophys. J. 2004, 600:L93.
25. Shah K., Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2005, 2:215-225.
26. Kanwar R.K., Chaudhary R., Tsuzuki T., Kanwar J.R. Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?. Nanomedicine (Lond.) 2012, 7:899-916.
27. Hao R., Yu J., Ge Z., Zhao L., Sheng F., Xu L., Li G., Hou Y. Developing Fe3O4 nanoparticles into an efficient multimodality imaging and therapeutic probe. Nanoscale 2013, 5:11954-11963.
28. Feng W., Zhou X., Nie W., Chen L., Qiu K., Zhang Y., et al. Au/polypyrrole@ Fe3O4 nanocomposites for MR/CT dual-modal imaging guided-photothermal therapy: an in vitro study. ACS Appl. Mater. Interfaces 2015, 7(7):4354-4367.
29. Kanwar R.K., Chaudhary R., Tsuzuki T., Kanwar J.R. Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages. Nanomedicine (Lond.) 2012, 7:735-749.
30. Ren F., Sheng W.Q., Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J. Gastroenterol. 2013, 19:2603-2611.
31. Du L., Wang H., He L. CD44 is of functional importance for colorectal cancer stem cells. Clin. Cancer Res. 2008, 14:7964-7967. (vol 14, pg 6751, 2008).
32. + in colorectal cancer. Oncol. Lett. 2014, 7:1544-1548.
33. Pavsic M., Guncar G., Djinovic-Carugo K., Lenarcic B. Crystal structure and its bearing towards an understanding of key biological functions of EpCAM. Nat. Commun. 2014, 5:4764.
34. Arumugam S., Miller M.C., Maliekal J., Bates P.J., Trent J.O., Lane A.N. Solution structure of the RBD1,2 domains from human nucleolin. J. Biomol. NMR 2010, 47:79-83.
35. Imrich S., Hachmeister M., Gires O. EpCAM and its potential role in tumor-initiating cells. Cell. Adh. Migr. 2012, 6:30-38.
36. Spizzo G., Fong D., Wurm M., Ensinger C., Obrist P., Hofer C., et al. EpCAM expression in primary tumor tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 2011, 64:415-420.
37. Denzel S., Maetzel D., Mack B., Eggert C., Barr G., Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009, 9:402.
38. Zhou G., Seibenhener M.L., Wooten M.W. Nucleolin is a protein kinase C-ζ substrate-connection between cell surface signaling and nucleus in pc12 cells. J. Biol. Chem. 1997, 272:31130-31137.
39. Fujita K.-I., Matsuda E., Sekine K., Iigo M., Tsuda H. Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 2004, 25:1961-1966.
40. Xiao Y., Monitto C.L., Minhas K.M., Sidransky D. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin. Cancer Res. 2004, 10:8683-8686.
41. Busser B., Sancey L., Brambilla E., Coll J.-L., Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim. Biophys. Acta (BBA) - Rev. Cancer 2011, 1816:119-131.
42. Deng L., Chen N., Li Y., Zheng H., Lei Q. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim. Biophys. Acta (BBA) - Rev. Cancer 2010, 1806:42-49.
43. Fang Y., Henderson F.C., Yi Q., Lei Q., Li Y., Chen N. Chemokine CXCL16 expression suppresses migration and invasiveness and induces apoptosis in breast cancer cells. Mediat. Inflamm. 2014, 2014:9. Article ID 478641.
44. Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer 2004, 11:709-724.
45. Tomita T., Fujii M., Tokumaru Y., Imanishi Y., Kanke M., Yamashita T., et al. Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. Cancer Lett. 2000, 156:83-91.
46. Gong Y., Scott E., Lu R., Xu Y., Oh W.K., Yu Q. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One 2013, 8:e77366.
47. Boshra H., Li J., Peters R., Hansen J., Matlapudi A., Sunyer J.O. Cloning, expression, cellular distribution, and role in chemotaxis of a C5a receptor in rainbow trout: the first identification of a C5a receptor in a nonmammalian species. J. Immunol. 2004, 172:4381-4390.
48. Nitta H., Murakami Y., Wada Y., Eto M., Baba H., Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol. Rep. 2014, 32:1715-1719.
49. Liu J., Guan X., Ma X. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J. Exp. Med. 2007, 204:141-152.
50. Ohmori Y., Fukumoto S., Hamilton T.A. Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J. Immunol. 1995, 155:3593-3600.
51. Dudich E., Semenkova L., Gorbatova E., Dudich I., Khromykh L., Tatulov E., et al. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumor Biol. J. Int. Soc. Oncodevel. Biol. Med. 1997, 19:30-40.
52. Ischenko I., Petrenko O., Hayman M.J. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc. Natl. Acad. Sci. 2014, 111:3466-3471.
53. Yang H., Lee S., Lee S., Kim K., Yang Y., Kim J.H., et al. Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. J. Clin. Invest. 2013, 123:418.
54. Adamson D.C., Shi Q., Wortham M., Northcott P.A., Di C., Duncan C.G., et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 2010, 70:181-191.
55. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002, 8:494-501.
56. Hartwell K.A., Muir B., Reinhardt F., Carpenter A.E., Sgroi D.C., Weinberg R.A. The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc. Natl. Acad. Sci. 2006, 103:18969-18974.
57. Chatterjee S., Heukamp L.C., Siobal M., Schöttle J., Wieczorek C., Peifer M., et al. Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J. Clin. Invest. 2013, 123:1732.
58. Cole L.A. HCG variants, the growth factors which drive human malignancies. Am. J. Cancer Res. 2012, 2:22.
59. Lau M., Klausen C., Leung P. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene 2011, 30:2753-2766.
60. Zhang Y., Lima C.F., Rodrigues L.R. In vitro evaluation of bovine lactoferrin potential as an anticancer agent. Int. Dairy J. 2015, 40:6-15.
61. Lin M.T., Chang C.C., Chen S.T., Chang H.L., Su J.L., Chau Y.P., Kuo M.L. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J. Biol. Chem. 2004, 279:24015-24023.
62. Mehta H.H., Gao Q., Galet C., Paharkova V., Wan J., Said J., et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011, 71:5154-5163.
63. Dymicka-Piekarska V., Guzinska-Ustymowicz K., Kuklinski A., Kemona H. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb. Res. 2012, 129:e47-e50.
64. Kumar S., Kishimoto H., Chua H.L., Badve S., Miller K.D., Bigsby R.M., et al. Interleukin-1α promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am. J. Pathol. 2003, 163:2531-2541.
65. Sun X., Mao Y., Wang J., Zu L., Hao M., Cheng G., et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014, 1-10. 10.1038/onc.2014.158.
66. Rupertus K., Sinistra J., Scheuer C., Nickels R.M., Schilling M.K., Menger M.D., et al. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin. Exp. Metastasis 2014, 31:447-459.
67. Carter B.Z., Mak D.H., Schober W.D., Cabreira-Hansen M., Beran M., McQueen T., et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006, 107:1555-1563.
68. Zhang L., Yan R., Zhang Q., Wang H., Kang X., Li J., et al. Survivin, a key component of the Wnt/β-catenin signaling pathway, contributes to traumatic brain injury-induced adult neurogenesis in the mouse dentate gyrus. Int. J. Mol. Med. 2013, 32:867-875.